---
title: "Galectin Therapeutics CMO Jamil Khurram disposes of 7,557 common shares worth $23,728.98"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290874252.md"
description: "Galectin Therapeutics CMO Jamil Khurram exercised options for 7,557 shares at $1.23 and sold them the same day at an average of $3.14 on June 23, 2026. Following these transactions, he holds zero common shares but retains 32,500 stock options."
datetime: "2026-06-25T20:07:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290874252.md)
  - [en](https://longbridge.com/en/news/290874252.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290874252.md)
generator: "portal-rs"
---

# Galectin Therapeutics CMO Jamil Khurram disposes of 7,557 common shares worth $23,728.98

-   Galectin Therapeutics Chief Medical Officer Jamil Khurram exercised stock options for 7,557 shares at USD 1.23 on June 23, 2026. \* Khurram sold 7,557 shares the same day at a weighted average price of USD 3.14. \* He held 0 shares of common stock following the transactions. \* He reported 32,500 stock options remaining after the exercise. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001133416-26-000057), on June 25, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [GALT.US](https://longbridge.com/en/quote/GALT.US.md)

## Related News & Research

- [Maze Therapeutics CSBO Atul Dandekar disposes of common shares worth $206,823.75](https://longbridge.com/en/news/297567588.md)
- [Monopar Therapeutics director Raymond Anderson sells USD 349,125 of common shares](https://longbridge.com/en/news/297238555.md)
- [Rapport Therapeutics Chief Development Officer Krishnaswamy Yeleswaram disposes of common shares worth $2.51 million](https://longbridge.com/en/news/297082004.md)
- [MPM BioVentures 2014 reports $612,948 Entrada Therapeutics common share sale](https://longbridge.com/en/news/297567230.md)
- [IBA publishes H1 2026 results presentation](https://longbridge.com/en/news/297180350.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**